Kymera Therapeutics revealed new patents on STAT6 inhibitors aimed at oncology, inflammation, fibrosis, and metabolic indications (d3aace0d1d6f498c). The disclosures describe small molecules designed to modulate STAT6 signaling, a transcription factor implicated in type 2 immune responses and tumor biology. Core finding: Kymera’s filing claims inhibitors that block STAT6‑mediated transcriptional programs, supporting potential utility across allergic inflammation, cancer immunomodulation, and fibrotic disease. The company contextualizes the work within its targeted protein degradation and small‑molecule discovery engine. For corporate strategy teams, the patents expand Kymera’s intellectual property footprint into STAT family targeting and may inform R&D partnerships or competitive assessments in immune and oncology spaces.